Bioresorbable Vascular Scaffold (ABSORB BVS); first report in Egyptian patients with 6month angiographic/IVUS follow up  by Khamis, Hazem et al.
The Egyptian Heart Journal (2014) 66, 227–232HO ST E D  BY
Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comORIGINAL ARTICLEBioresorbable Vascular Scaﬀold (ABSORB BVS);
ﬁrst report in Egyptian patients with 6 month
angiographic/IVUS follow up* Corresponding author. Tel.: +20 1001625073; fax: +20 224557
710.
E-mail address: Hazemkhamis62@yahoo.com (H. Khamis).
Peer review under responsibility of Egyptian Society of Cardiology.
1110-2608 ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
http://dx.doi.org/10.1016/j.ehj.2013.09.005Hazem Khamis a,*, Khalid Shokry b, Ahmed Ramzy c, Ahmed Samir da October 6th University, Egypt
b Military Academy, Egypt
c Benha University, Egypt
d Cairo University, EgyptReceived 25 June 2013; accepted 25 September 2013
Available online 11 November 2013KEYWORDS
ABSORB BVS;
Bioresorbable Vascular
Scaffold;
Native coronary artery
stenosisAbstract Objective: To evaluate the feasibility, efﬁcacy, and safety of the ABSORB BVS
(Bioresorbable Vascular Scaffold) for the treatment of de novo native coronary artery stenosis.
Methods: Thirty patients with ischemic heart disease were selected between September 2012 and
December 2012 and received ABSORB BVS for the treatment of de novo native signiﬁcant
ccoronary artery stenosis. Patients were followed up for six months after the procedure. In each
patient, the treated segment and the periscaffold segments (5 mm proximal and distal to the scaffold
edge) were analyzed by Quantitative coronary angiography (QCA) and phased-array intravascular
ultrasound (IVUS) catheters in paired matched angiographic views after the procedure and at fol-
low-up. The major clinical end point was ischemia-driven major adverse cardiac events (ID-MACE)
deﬁned as a composite of cardiac death, myocardial infarction or ischemia-driven target lesion
revascularization.
Results: Overall the scaffold area remained unchanged. The angiographic late lumen loss
amounted to 0.27 ± 0.32 mm with an IVUS relative decrease in minimal lumen area of 1.94%
(p= 0.12), without signiﬁcant changes in the mean lumen area. After 2 weeks, 1 patient presented
with STEMI, control coronary angiography revealed a patent stent with thrombus distal to it that
was treated with a metallic drug-eluting stent (Xience V). There were no cardiac deaths or ischemia-
driven target lesion revascularizations. At six months the hierarchical ID-MACE was 3.3%.
Conclusions: ABSORB BVS seems an attractive option for the treatment of signiﬁcant de novo
native coronary artery stenosis with low risk of serious adverse events.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
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Drug-eluting stents (DES) were conceived as the next evolu-
tionary step in improving the limitations of bare metal stents
(BMS). Initial studies were highly promising, with large-scale
reductions in restenosis rates that were reported at 0% in
highly selective lesions 4% and up to 16% in a broader range
of patients and lesions.1
A potential complication subsequently became evident with
ﬁrst-generation DES, namely that of subacute and late stent
thrombosis as a consequence of delayed healing of the perma-
nent metallic struts. Furthermore, late acquired malapposition
of the struts implanted in a thrombotic rich milieu was also
demonstrated to be a potential issue.2
The prospect of a temporary vascular stent, termed ‘‘scaf-
fold’’ due to its being based on a temporary bioresorbable plat-
form, has been always a goal of the interventional community.
Such a device could offer transient radial strength to resist
acute vessel recoil, and at a later stage would be fully resorbed,
leading to restoration of the vessel’s biological properties.3
The polymeric material as an implantation medium poten-
tially has numerous advantages compared to metal. The main
challenges faced by the ABSORB (BVS) are its limited disten-
sibility, and therefore its suitability for implantation in
appropriately sized vessels. Consequently, at present Quanti-
tative coronary angiography (QCA) guidance is mandatory
for implantation of the device. Although the radial strength
of the ABSORB (BVS) has been reported to be comparable
to metallic stents, this is provided the BVS is deployed within
the limits of its size. If the BVS is over-stretched beyond its
designed limits, it has been shown to lose some of its radial
strength and may possibly fracture. Much effort has been in-
vested in improving its supportive properties, with the intro-
duction of a new strut design in order to enhance the
distensibility of the device while maintaining its radial
strength, features which are expected in the next generation
BVS.3
Bioabsorbable drug-eluting vascular scaffolds (BVS;
Abbott Vascular, Santa Clara, Calif) are novel approach that
provides transient vessel support with drug delivery capability
without the long-term limitations of metallic drug-eluting
stents such as permanent caging with or without
malapposition.4
Permanent metallic stenting also may preclude surgical
revascularization, prevent late lumen enlargement, result in
jailing of side branches, and hamper noninvasive imaging of
coronary arteries with multislice computed tomography and
MRI.5
Bioresorbable technology is an alternative and challenging
therapeutic approach for the treatment of coronary artery dis-
ease. Although the scenario of a dynamic device that ‘‘does the
job and disappears’’, leading to the restoration of vascular
physiology, is here (‘‘vascular reparative therapy’’), this inno-
vative and rapidly progressing technology is still in its infancy.3
2. Aim of the work
The aim of this study was assessment of the safety and efﬁcacy
of the BVS (Bioresorbable Vascular Scaffold) for the treatment
of de novo native coronary artery stenosis.3. Methods
3.1. Study design and patients
The study included 30 cases admitted to the catheterization
laboratory in Wadi El-Neel hospital diagnosed as having ische-
mic heart disease with signiﬁcant coronary artery stenosis
necessitating PCI. We included full history, clinical evaluation,
Standard 12 leads surface ECG, Echocardiography, Ischemic
driven non-invasive test for controversy patient with chest
pain.3.2. Inclusion criteria
- Patients who were able to verbally conﬁrm understand-
ing of risks, beneﬁts and treatment alternatives of receiv-
ing the Everolimus Eluting BVS and he/she or his/her
legally authorized representative provided written
informed consent prior to any clinical investigation
related procedure.
- Patients must have evidence of myocardial ischemia.
- Patients must agree to undergo all clinical investigation
plan required.
- Target lesion(s) were:
- De novo located in a native coronary artery.
- Measure 624 mm in length by visual estimation.
- In a major artery or branch with a visually estimated steno-
sis of P50% and <100% with a TIMI ﬂow of P1.
3.3. Exclusion criteria
- Patients with LV systolic dysfunction (EF < 30%), cardio-
genic shock.
- Patients who received a heart transplant.
- Patients who received or scheduled to receive chemotherapy
for malignancy within 30 days prior to or after the
procedure.
- Patients receiving immunosuppressive therapy.
- Patients with known hypersensitivity or contraindication to
aspirin, heparin, clopidogrel, everolimus, poly L-lactide
(PLLA), poly DL-lactide (PDLLA) or contrast sensitivity
that cannot be adequately pre-medicated.
- Patients with end stage liver or renal disease.
- Patients with recent bleeding or cerebrovascular accident
(CVA) or transient ischemic neurological attack (TIA)
within the past six months.
- Pregnant or nursing patients and those who plan pregnancy
during the clinical investigation.
- Patients who received brachytherapy in any epicardial
vessel.
- Target lesion(s) meet any of the following criteria:
o Any vessel having any previous metallic stent.
o Any arterial or venous grafts.
o Excessive tortuosity proximal to or within the lesion
(extreme angulation (P90%) proximal to or within
the lesion), heavy calciﬁcation or in-stent restenosis.
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BVS balloon-expandable device consists of a polymer back-
bone of poly L-lactide (PLLA) coated with a thin layer of a
1:1 mixture of poly DL-lactide (PDLLA) polymer and the anti-
proliferative drug everolimus to form an amorphous drug-elut-
ing coating matrix containing 100 lg everolimus/cm2 scaffolds.
The implant is radiolucent but has 2 platinum markers at each
end that allow easy visualization on angiography and other
imaging modalities. PDLLA allows controlled release of the
everolimus so that 80% is eluted in 30 days; the elution rate,
tissue concentration, and dose density of everolimus for the
BVS device are similar to the XIENCE Veverolimus-eluting
stent.
Both PLLA and PDLLA are fully resorbable. The polymer
degrades via a bulk erosion process through hydrolysis of the
ester bonds in the backbone. The resulting lactic acid mono-
mer and oligomers eventually leave the polymer matrix once
they reach high enough diffusivity and water solubility. They
are rapidly metabolized in surrounding tissues and blood by
entering the pyruvate and Kreb energy cycles. In this second
iteration of the scaffold device, the hydrolysis of the polymer
has been slowed through a proprietary manufacturing process.
According to preclinical studies, the time for complete absorp-
tion of the polymer backbone is assumed to be 2 years,
whereas the polymer coating is absorbed faster.6
3.5. Study procedure
Target lesions were treated using standard interventional tech-
niques with mandatory pre-dilatation. Post-dilatation with a
balloon shorter than the implanted stent was allowed at the
operator’s discretion (if an optimal angiographic result was
not obtained immediately after scaffold deployment). Bailout
stenting with Xience-V for edge dissection and insufﬁcient cov-
erage of the lesion was recommended if needed. Treatment
with aspirin was started at least 24 h before the procedure
and continued throughout the length of the clinical investiga-
tion, followed by lifelong aspirin treatment. A loading dose
of 300 mg clopidogrel was administered before the procedure,
followed by 75 mg daily for a minimum of 6 months.
3.6. Deﬁnitions
Clinical device success was deﬁned as successful delivery and
deployment of the clinical investigation scaffold at the in-
tended target lesion with attainment of a ﬁnal residual stenosis
of <20% of the target lesion by QCA (by visual estimation if
QCA unavailable). Bailout stenting was not considered a de-
vice failure. Clinical procedure success was deﬁned as above
using any adjunctive device without the occurrence of ische-
mia-driven major adverse cardiac events up to 7 days after
the index procedure.
The composite end point was cardiac death, any myocar-
dial infarction, or ischemia-driven target lesion revasculariza-
tion for a QCA DS (diameter stenosis) of P50% either with
symptoms or ischemia or with DS P70% at the time of
scheduled (180 ± 14 days) or unscheduled angiography. For
non-Q-wave myocardial infarction, elevation of creatine
kinase (CK) levels >2 times the upper limit of normal with
elevated CK-MB was required.73.7. Angiographic assessment
In all patients, the treated segment and the peri-scaffold seg-
ments (deﬁned by a length of 5 mm proximal and distal to
the scaffold edge) were analyzed by QCA in paired matched
angiographic views after the procedure and at follow-up. The
following QCA parameters were computed: minimal luminal
diameter (MLD), reference vessel diameter obtained by an
interpolated method, late loss, and binary restenosis, ascer-
tained in scaffold, in periscaffold segment, and in segment
(scaffold plus peri-scaffold segments).
Information on the type of the largest balloon used dur-
ing procedure was also collected. The predicted balloon
diameter was obtained from the chart of Post-dilatation bal-
loon provided by the manufacturer using the balloon diam-
eter and the pressure during the procedure. In addition, the
Synergy Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery (SYNTAX) score was calculated
to quantify the complexity of coronary anatomy using ded-
icated software available at the website (www.syntax-
score.com) that integrates the number of lesions with their
speciﬁc weighting factors based on the amount of myocar-
dium distal to the lesion and the morphological features of
each single lesion.83.8. IVUS gray-scale analysis
Treated vessels after the procedure and at follow-up were
examined with phased-array IVUS catheters (Eagle Eye,
Volcano Corp, Rancho Cordova, Calif) using an automated
pullback at 0.5 mm/s. The region of interest beginning 5 mm
distal to and extending 5 mm proximal to the treated seg-
ment was examined. The vessel area, scaffold area, lumen
area, intrascaffold neointimal area, and luminal area stenosis
were measured with a computer-based contour detection
program.
The percentage of lumen area stenosis was calculated as 100
times the mean lumen cross-sectional area within the scaffold
minus the minimal lumen area within scaffold divided by mean
lumen cross sectional area. Incomplete apposition was deﬁned
as 1 or more scaffold struts separated from the vessel wall; ac-
quired late incomplete apposition was deﬁned as incomplete
apposition at follow-up that was not present after the
procedure.9
3.9. Statistical analysis
This was a feasibility study designed to provide preliminary
information on the performance of the BVS. The sample size
was not deﬁned on the basis of an end-point hypothesis but
rather to provide information on device performance. For bin-
ary variables, percentages were calculated. When provided, the
95% conﬁdence intervals were computed with the gaussian
approximation, taking into account the paired analysis. Paired
comparisons between post procedural and follow-up results
were done by a Wilcox on signed-rank test.
Because no formal hypothesis testing was planned for
assessing the success of the study, no statistical adjustment
was applied. P values presented here are exploratory analyses
only and should therefore be interpreted cautiously.
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Thirty patients were enrolled, and the investigational device
was successfully implanted in all patients (Table 1). No bail-
out stents were implanted. There were no deaths, either
peri-procedurally or at 6 months. At 2 weeks, 1 patient pre-
sented with STEMI, control coronary angiography revealed
a patent stent with thrombus distal to stent that was treated
with a metallic drug-eluting stent (Xience V), ID-MACE
3.3%.
4.1. Angiographic results
Table 2 summarizes the results of QCA data at baseline and at
follow-up. At follow-up, the intrascaffold MLD decreased
from 2.32 ± 0.28 to 2.13 ± 0.29 mm (P< 0.001). There were
no signiﬁcant changes in MLD at the proximal and distal
edges of the scaffold. The angiographic late loss was
0.27 ± 0.32 mm. In-scaffold binary restenosis was 0%,
whereas 1 proximal edge restenosis was documented by angi-
ography in a symptomatic patient (1 of 30; 3.3% in-segment
binary restenosis).
4.2. Gray-scale IVUS
The results of gray-scale IVUS are presented in Table 3. At
follow-up, there was no signiﬁcant change in vessel area,
but decreases in mean scaffold area, minimal scaffold area,
mean lumen area, and minimum lumen area attained signiﬁ-
cance, although the relative decreases at follow-up of these
parameters were small, 2.0%, 4.6%, 3.1%, and 5.4%,
respectively.
On baseline IVUS, 4 patients showed incomplete scaf-
fold apposition (ISA) with respective volumes of 27.7, 2.6,
5.7, and 1.1 mm3. One ISA persisted at follow-up, and 3
ISAs resolved. At follow-up, 3 patients developed a late ac-Table 1 Baseline characteristics.
Characteristic
Age, mean ± SD (y)
Male gender, n (%)
Current smoker, n (%)
Diabetes mellitus, n (%)
Hypertension requiring medication, n (%)
Hyperlipidemia requiring medication, n (%)
Prior myocardial infarction, n (%)
SYNTAX score (mean ± SD)
Target vessel, n (%)
Left anterior descending artery
Left circumﬂex
Right coronary artery
AHA/ACC lesion classiﬁcation, n (%)
A
B1
B2
Mean reference vessel diameter, mean ± SD (mm)
MLD (Minimum Luminal Diameter), mean ± SD (
DS (Diameter Stenosis), mean ± SD (%)
Lesion length, mean ± SD (mm)quired ISA with respective volumes of 3.0, 1.7, and
1.5 mm3.
5. Discussion
In this study, we reported that the late luminal loss was
0.19 mm documented at 6 months which was in the range ob-
served with current metallic drug-eluting stents. Besides, ab-
sence of stent area shrinkage, in conjunction with the growth
of a small amount of neointima resulted in a very modest
reduction in lumen area over 6-month period.
5.1. IVUS analysis of late recoil
Grayscale IVUS and IVUS-based imaging modalities during
the last years have become useful in the assessment not only
of drug eluting stent, but also of new Bioresorbable Vascular
Scaffolds. Although IVUS resolution is not sufﬁcient for deter-
mining stent coverage (optical coherence tomography is the
gold standard), serial IVUS can measure intimal hyperplasia,
assess acute and late incomplete stent apposition, detect the
presence and persistence of edge dissections, study edge effects
and look for causes of restenosis and thrombosis. In addition
other IVUS-based imaging modalities, such as IVUS-VH,
iMAP or palpography, can be used to study the serial compo-
sitional and mechanical changes of the plaque behind stent
struts and also to follow the bioresorption of the new biore-
sorbable scaffolds, analyzing the backscattering signal coming
from the polymeric struts.
The 20-MHz IVUS catheter is not a sheath-based pullback
system, and the mechanical pullback of the IVUS catheter
itself (0.5 mm/s) can be impeded by calcium or tortuosity, so
the measurement of the scaffold length is not always reliable.
Therefore, we reported our IVUS measurements in area units
and not in volume (area time length) units. Although the term
late recoil has been used frequently in interventional cardiol-Intention to treat, n= 30
62 ± 8
22 (73)
7 (23.3)
11 (36.6)
18 (60)
18 (60)
13 (43.3)
7.98 ± 2.27
12 (40)
8 (27)
10 (33)
1 (3.3)
15 (50)
13 (43.3)
2.62 ± 0.37
mm) 1.26 ± 0.23
64 ± 13
12.2 ± 3.4
Table 2 Paired QCA analysis (n= 30).
Intention-to-treat population (30 pairs)
Proximal In-scaﬀold Distal In-segment
Reference vessel diameter, mean ± SD (mm)
After the procedure 2.67 ± 0.40 2.76 ± 0.38 2.64 ± 0.36 2.72 ± 0.40
At 6 month follow-up 2.72 ± 0.36 2.65 ± 0.37 2.53 ± 0.38 2.60 ± 0.40
P between after the procedure and follow-up <0.0001 <0.0001 <0.0001 0.0014
MLD, mean ± SD (mm)
After the procedure 2.46 ± 0.52 2.32 ± 0.28 2.24 ± 0.45 2.09 ± 0.37
At 6 month follow-up 2.38 ± 0.49 2.13 ± 0.29 2.15 ± 0.38 1.97 ± 0.35
P between after the procedure and follow-up 0.1 <0.0001 0.1 0.02
Immediate gain, mean ± SD (mm) 1.26 ± 0.36
Late loss, mean ± SD (mm) 0.07 ± 0.27 0.27 ± 0.32 0.07 ± 0.30 0.11 ± 0.28
DS, mean ± SD (%)
After the procedure 14.5 ± 10.8 15.5 ± 6.1 15.3 ± 9.8 22.9 ± 8.1
At 6 month follow-up 12.7 ± 11.5 19.2 ± 7.6 14.8 ± 9.40 24.0 ± 9.6
P between after the procedure and follow-up 0.086 0.0005 0.36 0.74
Table 3 IVUS results: paired gray-scale IVUS measurements per lesion, intention to treat (n= 30).
Post PCI At 180 days Diﬀerence (95% CI) P
(Mean ± SD) (Mean ± SD) Based on individual data (%)
Vessel area (mm2) 14.22 ± 3.75 14.49 ± 3.67 2.4 ± 7.4 (0.08–4.87) 0.06
Scaﬀold area (mm2) 6.58 ± 1.17 6.44 ± 1.11 2.0 ± 4.8 (3.56–0.34) 0.015
Minimum scaﬀold area (mm2) 5.51 ± 1.02 5.24 ± 0.93 4.6 ± 7.4 (7.05–2.12) <0.001
Neointimal hyperplasia area (mm2) – 0.08 ± 0.13 – –
Mean lumen area (mm2) 6.60 ± 1.22 6.37 ± 1.12 3.1 ± 7.0 (5.45–0.75) <0.005
Minimum lumen area (mm2) 5.49 ± 1.03 5.17 ± 0.97 5.4 ± 8.7 (8.29–2.47) <0.001
Lumen area stenosis (%) 16.8 ± 4.8 18.7 ± 7.5 14.6 ± 40.4 (1.09–28.04) 0.24
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elastic membrane area, in the present case, it relates more spe-
ciﬁcally to the area reduction of the treated segment, a phe-
nomenon not previously observed in metallic stents which
was attributed to early alteration of the mechanical integrity
of the scaffold.
Late loss measurements by QCA, scaffold area assessment
by gray-scale IVUS all conﬁrm the almost complete
disappearance of this phenomenon. On gray-scale IVUS, the
intrascaffold neo-intima is conventionally measured from end-
oluminal leading edges of echogenic struts and is minimal
(0.07 mm2) in the present analysis.
6. Limitations
A relatively small number of patients with a short duration of
follow-up.
7. Conclusions
The promising results at 6 months of bioresorbable drug-
eluting scaffold constitute proof of concept that this device
can adequately revascularize coronary vessels and prevent
restenosis. Considering the favorable outcomes of BVS, it is
deemed appropriate and timely to initiate a randomized piv-
otal trial comparing a metallic drug-eluting stent with this
drug-eluting Bioresorbable Vascular Scaffold.Conﬂict of interest
None declared.
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